Ostenil plus solution and / in / with 40mg / 2ml 2ml syringe

Description

Composition
Active substance:
1 ml of isotonic solution (pH 7.3) containing 20.0 mg of sodium hyaluronate and sodium chloride, sodium hydrogenphosphate, sodium dihydrogenphosphate, mannitol and water for injection.
Description:
This combination of non-modified high-concentration hyaluronic acid (HA) of non-animal origin and mannitol.
Product form:
The sterile-filled syringe containing 40 mg / 2 ml Ostenil® Plus in sterile packaging.
Contraindications
Should not be used in patients with severe sensitivity to any of its ingredients.
Precautions: Observe general precautions for intra-articular injections, as well as measures to prevent joint infection. Ostenil® Plus should only be entered into the joint cavity, if necessary, using visual controls. Avoid contact of the drug into the surrounding tissue or blood vessels! When inflammation in the joint exercise extreme caution. Not recommended for use in rheumatoid arthritis in the active phase and ankylosing spondylitis. Ostenil® Plus is not recommended for use in children, pregnant and lactating women.
Dosage
20 mg / ml
Indications
Pain and restricted mobility in degenerative – degenerative and traumatic changes of the knee and other synovial joints.
Interaction with other drugs
Information about the incompatibility Ostenil® Plus with other solutions for intra-articular application for the time being absent. During the first days after the injection can be recommended use of oral analgesic and anti-inflammatory drugs.
pharmachologic effect
Pharmacodynamics:
Synovial liquid, being viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints. Due to its lubricating and shock absorbing properties, synovial fluid provides a normal pain-free movement, which is especially important in supporting the joints that can withstand a greater load. In addition, she is responsible for the cartilage nutrition. In degenerative processes in the joints, such as osteoarthritis, viscoelasticity of the synovial fluid is markedly reduced, which negatively affects its lubricating and shock-absorbing functions. As a result of increased mechanical load on the articular cartilage, which leads to their destruction, and, consequently, to the emergence of pain and limited mobility in the joint. Intraarticular administration of hyaluronic acid in high purity contributes to improving the viscoelastic properties of synovial fluid. This improves its lubricating and shock-absorbing functions and reduces mechanical overload of the affected joint. Typically, this entails a reduction in pain and improvement in mobility, which may persist for several months after treatment.
Ostenil® Plus – clear solution of highly purified native sodium hyaluronate obtained by fermentation and containing no animal proteins. The composition also includes Ostenil® Plus mannitol, which minimizes the activity of free radicals, thus providing stability of the molecular structure of sodium hyaluronate. High security profile Ostenil® Plus certified biocompatibility test.
Conditions of supply of pharmacies
Without recipe
side effects
After intraarticular injection Ostenil® Plus can be observed the local secondary phenomena such as pain, feeling of heat, redness and swelling. Imposition of ice on the punctured joint for 5-10 minutes, allows to stop such events.
Storage conditions
Stored at 2 ° C-25 ° C in the reach of children. Do not freeze. The drug appears to be damaged sterile packaging or syringe, as well as beyond the expiration date (listed on the box) is not subject to use.
Dosing and Administration
Is injected into the cavity of the affected joint once. As indicated, the treatment may be supplemented by one or two injections with an interval of 14 days. At the same time, you can perform the injections and other joints. In the presence of joint effusion must first make its evacuation, to ensure tranquility and joint use cold therapy or intraarticular administration of the corticosteroid drug. OSTENIL®plyus can enter in two or three days after these procedures. The content and the outer surface of the syringe filled with sterile Ostenil® Plus, while not broken integrity of packaging and corking of the syringe system. The closure system consists of the protective cap and the luer lock lid for protection against unauthorized opening. Remove the filled syringe with Ostenil® Plus from its sterile packaging. Fold the lid for protection against unauthorized opening of the syringe in one and other sides so that its locking webs broke (see. Figure). Carefully remove the top cover with the protective cap. Attach the required size (18 – 25 G) sterile needle and fix it by turning slightly. Before release from the injection syringe, air bubbles, if any.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist